Prelude Therapeutics (PRLD) Capital Expenditures (2019 - 2026)
Prelude Therapeutics (PRLD) posted Capital Expenditures of $20000.0 for Q2 2025, down 57.45% sequentially from $47000.0 in Q1 2025, and down 94.43% YoY from $359000.0 in Q2 2024.
Prelude Therapeutics (PRLD) Capital Expenditures (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at $20000.0 in Q2 2025.
- Quarterly Capital Expenditures fell 94.43% year-over-year to $20000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $20000.0 (up 108.62% YoY) and the FY2025 annual result came in at $67000.0, up 570.0% from the prior year.
- Capital Expenditures declined to $20000.0 in Q2 2025 per PRLD's latest filing, from $47000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.6 million in Q3 2021 and troughed at -$1.4 million in Q3 2022.
- A 5-year average of $249222.2 and a median of $321500.0 in 2022 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 2887.88% in 2021, down 774.16% in 2021.
- Over 5 years, Capital Expenditures stood at -$1.2 million in 2021, then surged by 80.9% to -$233000.0 in 2022, then soared by 584.55% to $1.1 million in 2023, then plunged by 162.09% to -$701000.0 in 2024, then soared by 102.85% to $20000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $20000.0, $47000.0, and -$701000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 28,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28,000.00 |
| Jun 30, 2026 | 28,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | -701,000.00 |
| Dec 31, 2024 | -701,000.00 |
| Sep 30, 2024 | 63,000.00 |
| Sep 30, 2024 | 63,000.00 |
| Jun 30, 2024 | 359,000.00 |
| Jun 30, 2024 | 359,000.00 |
| Mar 31, 2024 | 289,000.00 |
| Mar 31, 2024 | 289,000.00 |
| Dec 31, 2023 | 1.13 Mn |
| Dec 31, 2023 | 1.13 Mn |
| Sep 30, 2023 | 591,000.00 |
| Sep 30, 2023 | 591,000.00 |
| Jun 30, 2023 | 983,000.00 |
| Jun 30, 2023 | 983,000.00 |